Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 29 studies.
Reviews & meta-analyses: 2 · Randomised trials: 3 · 2004–2026
Showing all 29 studies, sorted by most relevant.
Marianne Pan, Chi-Hsuan Sung, R. Pilla, et al.
Pets, 2025
The purpose of this study was to assess the practical implications of supplementing soluble fiber in the diet of dogs. Dogs with a history of managed or active chronic enteropathy were randomized to receive either wheat dextrin (fiber group) or maltodextrin (placebo group) mixed with food once daily for 28 days. Owners recorded a daily fecal score one week prior to and during the supplementation period. Shallow shotgun sequencing, quantitative PCR abundances of core bacterial taxa, and short-chain fatty acid (SCFA) concentrations via gas chromatography/mass spectrometry were performed on fecal samples collected before and after supplementation. Seventeen dogs completed the study (fiber group: nine dogs; placebo group: eight dogs). The change in fecal score differed between groups, with the fiber group developing softer stools (p = 0.03). Alpha diversity, quantified PCR abundances of the SCFA-producing taxa, and fecal SCFA concentrations were not different after supplementation in either group. Fecal microbial communities differed between baseline and day 28 for fiber and placebo groups (p = 0.02, respectively); however, the size effect (ANOSIM R = 0.18 and R = 0.26, respectively) was minimal. In this small group of dogs fed variable commercial diets, the additional intake of wheat dextrin powder supplement was well accepted, but had minimal discernable clinical benefit, and could soften stools.
Abstract licence: CC BY
Kruger K, van der Veen H, Beigy M, et al.
2026
Global lifespan is rising, alongside increasing age-related conditions. Cognitive disorders such as dementia, are projected to triple in number by 2050. Currently, no cure is available for Alzheimer's disease (AD), the most common form of dementia, and the need for preventative strategies is paramount. Subjective cognitive decline plus (SCD+) lies on the AD continuum, with increased risk of accelerated cognitive decline, providing an ideal target group for early intervention. The microbiota-gut-brain axis (MGBA) is an emerging avenue for prevention, as dietary fibres may beneficially modulate microbiota and microbial metabolites, such as short chain fatty acids and tryptophan-indoles, resulting in improved gastrointestinal and cognitive functioning. PRECODE is a four-armed, randomised, double-blinded, placebo-controlled trial in 164 older adults (60-79 years) with SCD+ and additional "LIfestyle for BRAin Health" (LIBRA) risk factors. The study aims to investigate 26 weeks of supplementation with chicory inulin, resistant dextrin, and seaweed polysaccharide compared to placebo (maltodextrin) on the MGBA. The primary outcome is effects on neurocognition, assessed by brain activation during working memory load measured with blood-oxygen level dependant functional magnetic resonance imaging (BOLD fMRI) and performance during 2-back task. The secondary outcomes include cognition by neuropsychological test battery, brain and intestinal health parameters, and immune and metabolic markers. Findings may guide new preventative modalities in preclinical AD and provide mechanistic insights into the MGBA in individuals at risk for cognitive decline. Clinical trial registration: https://clinicaltrials.gov/study/NCT06433037.
Abstract licence: CC BY
Sun Y, Niu X, Wang Y, et al.
2025
- alpha-Amylases
- alpha-Glucosidases
- Blood Glucose
OBJECTIVE: Postprandial hyperglycemia is a major risk factor for type 2 diabetes and cardiovascular disease. Inhibition of α-amylase and α-glucosidase can attenuate postprandial glycemic response (PPGR). This study aimed to investigate the inhibitory effects of mulberry leaf and corn silk on these enzymes in vitro and their impact on postprandial glucose (PG) levels in prediabetic individuals using milk-based matrices. RESEARCH DESIGN AND METHODS: In vitro, enzyme inhibition was assessed using the DNS method (α-amylase) and pNPG method (α-glucosidase). A randomized crossover trial was conducted in 11 prediabetic individuals with four interventions: pure milk; lactose-hydrolyzed milk; lactose-hydrolyzed milk with mulberry leaf, corn silk, and resistant dextrin; and GOS milk with mulberry leaf and corn silk. PPGR was assessed by area under the glucose curve, 1 and 2 h PG, maximum PG, and 2 h glucose excursion. Paired Wilcoxon signed-rank tests were used for comparisons. RESULTS: Mulberry leaf and corn silk extracts inhibited both enzymes dose-dependently, with synergistic effects. No significant differences in PPGR indices were observed across interventions in the overall prediabetic individuals. However, in the overweight subgroup, the combination of GOS milk supplemented with mulberry leaf and corn silk significantly reduced 1 h PG (median difference [P25, P75]: -0.84 mmol/L [-1.05, -0.49]), maximum PG (-0.54 mmol/L [-0.75, -0.25]), and glucose excursion (-0.62 mmol/L [-0.75, -0.24]) compared to pure milk. CONCLUSIONS: Mulberry leaf and corn silk extracts inhibit α-amylase and α-glucosidase in vitro and may attenuate postprandial glucose excursions in overweight prediabetic individuals when delivered in a GOS milk matrix.
Abstract licence: CC BY
J. Slavin, V. Savarino, A. Paredes-Diaz, et al.
Journal of International Medical Research, 2009
- Health
- Dextrins
- Disease
Debaprasad Ghosh, Anushka Jain, Mansi Tyagi, et al.
Combinatorial chemistry & high throughput screening, 2024
- Dextrins
- Polysaccharides
- Drug Delivery Systems
Travest J. Woodbury, L. Mauer
Food research international, 2023
- Amylose
- Starch
- Fructose
Howard EJ, Meyer RK, Weninger SN, et al.
2024
- Gastrointestinal Microbiome
- Dietary Fiber
- Homeostasis
BACKGROUND: The gut microbiota contributes to metabolic disease, and diet shapes the gut microbiota, emphasizing the need to better understand how diet impacts metabolic disease via gut microbiota alterations. Fiber intake is linked with improvements in metabolic homeostasis in rodents and humans, which is associated with changes in the gut microbiota. However, dietary fiber is extremely heterogeneous, and it is imperative to comprehensively analyze the impact of various plant-based fibers on metabolic homeostasis in an identical setting and compare the impact of alterations in the gut microbiota and bacterially derived metabolites from different fiber sources. OBJECTIVES: The objective of this study was to analyze the impact of different plant-based fibers (pectin, β-glucan, wheat dextrin, resistant starch, and cellulose as a control) on metabolic homeostasis through alterations in the gut microbiota and its metabolites in high-fat diet (HFD)-fed mice. METHODS: HFD-fed mice were supplemented with 5 different fiber types (pectin, β-glucan, wheat dextrin, resistant starch, or cellulose as a control) at 10% (wt/wt) for 18 wk (n = 12/group), measuring body weight, adiposity, indirect calorimetry, glucose tolerance, and the gut microbiota and metabolites. RESULTS: Only β-glucan supplementation during HFD-feeding decreased adiposity and body weight gain and improved glucose tolerance compared with HFD-cellulose, whereas all other fibers had no effect. This was associated with increased energy expenditure and locomotor activity in mice compared with HFD-cellulose. All fibers supplemented into an HFD uniquely shifted the intestinal microbiota and cecal short-chain fatty acids; however, only β-glucan supplementation increased cecal butyrate concentrations. Lastly, all fibers altered the small-intestinal microbiota and portal bile acid composition. CONCLUSIONS: These findings demonstrate that β-glucan consumption is a promising dietary strategy for metabolic disease, possibly via increased energy expenditure through alterations in the gut microbiota and bacterial metabolites in mice.
Abstract licence: CC BY-NC-ND
Xinyang Chen, Yinchen Hou, Aimei Liao, et al.
Biomolecules, 2024
- Gastrointestinal Microbiome
- Insulin Resistance
- Dextrins
Systemic chronic inflammation is recognized as a significant contributor to the development of obesity-related insulin resistance. Previous studies have revealed the physiological benefits of resistant dextrin (RD), including obesity reduction, lower fasting glucose levels, and anti-inflammation. The present study investigated the effects of RD intervention on insulin resistance (IR) in Kunming mice, expounding the mechanisms through the gut microbiome and transcriptome of white adipose. In this eight-week study, we investigated changes in tissue weight, glucose–lipid metabolism levels, serum inflammation levels, and lesions of epididymal white adipose tissue (eWAT) evaluated via Hematoxylin and Eosin (H&E) staining. Moreover, we analyzed the gut microbiota composition and transcriptome of eWAT to assess the potential protective effects of RD intervention. Compared with a high-fat, high-sugar diet (HFHSD) group, the RD intervention significantly enhanced glucose homeostasis (e.g., AUC-OGTT, HOMA-IR, p < 0.001), and reduced lipid metabolism (e.g., TG, LDL-C, p < 0.001) and serum inflammation levels (e.g., IL-1β, IL-6, p < 0.001). The RD intervention also led to changes in the gut microbiota composition, with an increase in the abundance of probiotics (e.g., Parabacteroides, Faecalibaculum, and Muribaculum, p < 0.05) and a decrease in harmful bacteria (Colidextribacter, p < 0.05). Moreover, the RD intervention had a noticeable effect on the gene transcription profile of eWAT, and KEGG enrichment analysis revealed that differential genes were enriched in PI3K/AKT, AMPK, in glucose-lipid metabolism, and in the regulation of lipolysis in adipocytes signaling pathways. The findings demonstrated that RD not only ameliorated IR, but also remodeled the gut microbiota and modified the transcriptome profile of eWAT.
Abstract licence: CC BY
Megumi Miyazaki, T. Maeda, N. Morita
Food Research International, 2004
Maria Molinos, Vera Carvalho, Dina M. Silva, et al.
Biomacromolecules, 2012
- Nanogels
- Adipates
- Biocompatible Materials
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.